Bo Kruse
Net Worth
Last updated:
What is Bo Kruse net worth?
The estimated net worth of Mr. Bo Kruse is at least $10,839,811 as of 31 May 2024. He owns shares worth $1,798,781 as insider, has earned $6,013,380 from insider trading and has received compensation worth at least $3,027,650 in Y-mAbs Therapeutics, Inc..
What is the salary of Bo Kruse?
Mr. Bo Kruse salary is $605,530 per year as Executive Vice President, Sec., Treasurer & Chief Financial Officer in Y-mAbs Therapeutics, Inc..
How old is Bo Kruse?
Mr. Bo Kruse is 53 years old, born in 1972.
What stocks does Bo Kruse currently own?
As insider, Mr. Bo Kruse owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Y-mAbs Therapeutics, Inc. (YMAB) | Executive Vice President, Sec., Treasurer & Chief Financial Officer | 210,877 | $8.53 | $1,798,781 |
What does Y-mAbs Therapeutics, Inc. do?
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Bo Kruse insider trading
Y-mAbs Therapeutics, Inc.
Mr. Bo Kruse has made 23 insider trades between 2020-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 66,046 units of YMAB stock on 14 May 2020. As of 31 May 2024 he still owns at least 210,877 units of YMAB stock.
Y-mAbs Therapeutics key executives
Y-mAbs Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Claus Juan Møller-San Pedro M.D., Ph.D. (62) Chief Executive Officer & Director
- Mr. Bo Kruse (53) Executive Vice President, Sec., Treasurer & Chief Financial Officer
- Mr. Thomas Gad (55) Founder, Chairman, Pres and Head of Bus. Devel. & Strategy